Lexicon Pharmaceuticals (LXRX) Stock Price, News & Analysis

Company Overview

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Key Stats

• Today's Range: $0.62 to $0.66
• 50-Day Range: $0.33 to $0.73
• 52-Week Range: $0.28 to $2.45
• Volume: 3.19 million shs
• Average Volume: 6.60 million shs
• Market Capitalization: $238.55 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.67
• Consensus Rating: Hold

Lexicon Pharmaceuticals Stock Analysis - MarketRank™

Lexicon Pharmaceuticals scored higher than 67% of companies evaluated by MarketBeat, and ranked 356th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

Lexicon Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Lexicon Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Lexicon Pharmaceuticals are expected to grow in the coming year, from ($0.66) to ($0.45) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Lexicon Pharmaceuticals is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lexicon Pharmaceuticals is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lexicon Pharmaceuticals has a P/B Ratio of 1.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

10.31% of the outstanding shares of Lexicon Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Lexicon Pharmaceuticals has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lexicon Pharmaceuticals has recently decreased by 9.82%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lexicon Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Lexicon Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

10.31% of the outstanding shares of Lexicon Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Lexicon Pharmaceuticals has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lexicon Pharmaceuticals has recently decreased by 9.82%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.83

News Sentiment

Lexicon Pharmaceuticals has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Lexicon Pharmaceuticals this week, compared to 4 articles on an average week.

Search Interest

Only 19 people have searched for LXRX on MarketBeat in the last 30 days. This is a decrease of -39% compared to the previous 30 days.

MarketBeat Follows

Only 8 people have added Lexicon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -70% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lexicon Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.50% of the stock of Lexicon Pharmaceuticals is held by insiders.

Percentage Held by Institutions

74.70% of the stock of Lexicon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LXRX Stock Analysis - Frequently Asked Questions

How have LXRX shares performed this year?

Lexicon Pharmaceuticals' stock was trading at $0.7385 at the start of the year. Since then, LXRX shares have decreased by 10.6% and is now trading at $0.6599.
View the best growth stocks for 2025 here.

How were Lexicon Pharmaceuticals' earnings last quarter?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced its earnings results on Tuesday, May, 13th. The biopharmaceutical company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.03. The biopharmaceutical company had revenue of $1.26 million for the quarter, compared to the consensus estimate of $1.26 million. Lexicon Pharmaceuticals had a negative trailing twelve-month return on equity of 107.38% and a negative net margin of 4,109.41%.
Read the conference call transcript.

Who are Lexicon Pharmaceuticals' major shareholders?

Lexicon Pharmaceuticals' top institutional shareholders include Siren L.L.C. (0.97%), AQR Capital Management LLC (0.32%), Charles Schwab Investment Management Inc. (0.32%) and Hennion & Walsh Asset Management Inc. (0.34%). Insiders that own company stock include International SCA Artal, Raymond Debbane, Lonnel Coats, Jeffrey L Wade and Wendy Mcdermott.
View institutional ownership trends.

How do I buy shares of Lexicon Pharmaceuticals?

Shares of LXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Lexicon Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Moderna (MRNA).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 5/23/2025
• Next Earnings (Estimated): 8/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:LXRX
• Previous Symbol: NASDAQ:LEXG
• CIK: 1062822
• Web: www.lexpharma.com
• Phone: (281) 863-3000
• Fax: 281-863-8010
• Employees: 140
• Year Founded: 1995

Price Target and Rating

• Average Stock Price Target: $3.67
• High Stock Price Target: $6.00
• Low Stock Price Target: $1.00
• Potential Upside/Downside: +455.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.51)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-177,120,000.00
• Net Margins: -4,109.41%
• Pretax Margin: -4,138.33%
• Return on Equity: -107.38%
• Return on Assets: -64.09%

Debt

• Debt-to-Equity Ratio: 0.56
• Current Ratio: 7.45
• Quick Ratio: 7.43

Sales & Book Value

• Annual Sales: $31.21 million
• Price / Sales: 7.64
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.38 per share
• Price / Book: 1.74

Miscellaneous

• Outstanding Shares: 361,492,000
• Free Float: 229,493,000
• Market Cap: $238.55 million
• Optionable: Optionable
• Beta: 1.07